Stock Events

Stock Events

Palisade Bio 

$1.81
65
+$0.06+3.43% Wednesday 04:59

Statistics

Day High
1.83
Day Low
1.78
52W High
-
52W Low
-
Volume
6,878
Avg. Volume
-
Mkt Cap
269.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Mar 2
$257,400
Dec 1
$234,000
Sep 1
$234,000
Jun 1
$234,000
Mar 1
$234,000
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12MayExpected
Q3 2025
Q4 2025
Next
-0.38
-0.27
-0.15
-0.04
Expected EPS
-0.036667
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-28.88MNet Income

Analyst Ratings

$11.20Average Price Target
The highest estimate is 25.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PALI.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, potentially overlapping with Palisade Bio's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences competes in the biopharmaceutical space, focusing on life-threatening diseases, similar to Palisade Bio's focus areas.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech company that develops innovative therapeutics, competing with Palisade Bio in the biopharmaceutical market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of pharmaceutical products, directly competing with Palisade Bio's business model.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes with Palisade Bio in the biotechnology and pharmaceuticals sector, focusing on serious diseases.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in the same biopharmaceutical field as Palisade Bio, developing therapies for complex and serious diseases.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is a global healthcare company that produces pharmaceuticals competitive with Palisade Bio's product pipeline.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a direct competitor in the pharmaceuticals sector, with a broad range of products that could compete with Palisade Bio's developments.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company with a diverse portfolio, including innovative medicines that could compete with Palisade Bio.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, competing with Palisade Bio in several therapeutic areas.

About

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Show more...
CEO
ISIN
US6963894026

Listings

F
DE
7NS0.F
XNAS
US
PALI
BOATS
BOATS
PALI.BOATS

0 Comments

Share your thoughts

FAQ

What is Palisade Bio stock price today?▼
The current price of PALI.BOATS is $1.81 USD — it has increased by +3.43% in the past 24 hours. Watch Palisade Bio stock price performance more closely on the chart.
What is Palisade Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Palisade Bio stocks are traded under the ticker PALI.BOATS.
What is Palisade Bio market cap?▼
Today Palisade Bio has the market capitalization of 269.7M
When is the next Palisade Bio earnings date?▼
Palisade Bio is going to release the next earnings report on May 12, 2026.
What were Palisade Bio earnings last quarter?▼
PALI.BOATS earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.04 USD resulting in a -11.11% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Palisade Bio revenue for the last year?▼
Palisade Bio revenue for the last year amounts to 0 USD.
What is Palisade Bio net income for the last year?▼
PALI.BOATS net income for the last year is -28.88M USD.
Does Palisade Bio pay dividends?▼
Yes, PALI.BOATS dividends are paid quarterly. The last dividend per share was 257,400 USD. As of today, Dividend Yield (FWD)% is 0%.
When did Palisade Bio complete a stock split?▼
Palisade Bio has not had any recent stock splits.